Drug Trial Radar · NCT05651022
Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jan 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Feb 28, 2023
Primary completion
Jun 30, 2027
Study completion Sep 30, 2027
Sponsor
- Lead sponsor
- Indaptus Therapeutics, IncIndustry
- Sponsor type
- Industry
- Collaborators
- Translational Drug Development
- First posted
- Dec 14, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
INDP-D101 is a Phase 1/2, open-label, multi-center, dose escalation and expansion study evaluating the safety, tolerability and clinical activity of Decoy20 as monotherapy and in combination with tislelizumab in patients with locally advanced or metastatic solid tumors.
Conditions
- Solid Tumor, Adult
- HCC - Hepatocellular Carcinoma
- CRC (Colorectal Cancer)
- Pancreatic Adenocarcinoma
- NSCLC Non-small Cell Lung Cancer
- Squamous Cell Cancer of the Head and Neck
- UC (Urothelial Cancer)
- MSI-H Cancer
Interventions
Decoy20Drug
Decoy20 is a novel, systemically administered multiple Toll-like receptor (TLR) agonist-based cancer immunotherapy.
TislelizumabDrug
Tislelizumab is a PD-1 inhibitor.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subjects with dose-limiting toxicities (DLTs)Time frame: Through study completion, up to 3 years
- Percentage of subjects with Adverse Events (AEs)Time frame: Through completion, up to 3 years
- Maximum Tolerated Dose (MTD) of Decoy20Time frame: Up to 2 years
- Recommended Phase 2 Dose (RP2D) of Decoy20Time frame: Up to 2.5 years
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
University of Southern California- Norris Cancer Center
Los Angeles, California
Hoag Memorial Hospital Presbyterian
Newport Beach, California
Winship Cancer Institute of Emory University
Atlanta, Georgia
The Barbara Ann Karmanos Cancer Institute
Detroit, Michigan
Washington University, Siteman Cancer Center
St Louis, Missouri
Atlantic Health System
Morristown, New Jersey
Roswell Park Comprehensive Cancer Center
Buffalo, New York
Gabrail Cancer & Research Center
Canton, Ohio
UH Seidman Cancer Center
Cleveland, Ohio
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Prisma Health Cancer Institute-ITOR
Greenville, South Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.